Scarica l'app Stockscreener
10.15
1.50%
0.15
Pre-mercato:
10.30
0.15
+1.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$10.00
Aprire:
$10.13
Volume 24 ore:
1.79M
Relative Volume:
1.45
Capitalizzazione di mercato:
$772.29M
Reddito:
$11.40B
Utile/perdita netta:
$-95.73M
Rapporto P/E:
-4.1429
EPS:
-2.45
Flusso di cassa netto:
$-64.37M
1 W Prestazione:
+5.29%
1M Prestazione:
+25.93%
6M Prestazione:
+19.27%
1 anno Prestazione:
+48.18%
Intervallo 1D:
$9.9003
$10.49
Intervallo di 1 settimana:
$9.3123
$10.49
Portata 52W:
$4.70
$10.49
Mind Medicine Inc Stock (MNMD) Company Profile
Nome
Mind Medicine Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Confronta MNMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
10.15 | 760.88M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Mind Medicine Inc Borsa (MNMD) Ultime notizie
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today - Yahoo Finance
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed (MNMD) Q2 2025 Earnings Call Transcript - AOL.com
MindMed Reports Strong Q2 2025 Results - The Motley Fool
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) large institutional owners must be happy as stock continues to impress, up 17% over the past week - simplywall.st
Mind Medicine (MindMed) (NASDAQ:MNMD) Earns Outperform Rating from Analysts at Oppenheimer - MarketBeat
Using RSI to spot recovery in Mind Medicine (MindMed) Inc.Weekly Breakout Forecast with Entry Zones - Newser
What makes Mind Medicine (MindMed) Inc. stock price move sharplyFree Trade Ready Stock Watch for Short Term - Newser
MindMed Reports Strong Phase 3 Trial Progress and Leadership Appointment - The Globe and Mail
Pattern recognition hints at Mind Medicine (MindMed) Inc. upsideAlpha Generation Strategy with Low Volatility - Newser
1 Reason to Buy MindMed (MNMD) - AOL.com
Roth Capital Issues Pessimistic Outlook for MNMD Earnings - Defense World
What MACD signals say about Mind Medicine (MindMed) Inc.AI-Based Reversal Point Prediction Signal - Newser
What is HC Wainwright’s Forecast for MNMD FY2028 Earnings? - Defense World
Oppenheimer Initiates Coverage on Mind Medicine (MindMed) (NASDAQ:MNMD) - Defense World
Is Mind Medicine stock a buy? - Cantech Letter
Mind Medicine upgraded at Oppenheimer on lead asset - MSN
A Quick Look at Today's Ratings for Mind Medicine(MNMD.US), With a Forecast Between $18 to $55 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM) - The Globe and Mail
MindMed Bets Big On Psychedelic Therapies With Cash To Spare - Finimize
Mind Medicine stock upgraded at Oppenheimer (MNMD:NASDAQ) - Seeking Alpha
Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating - AInvest
Mind Medicine resumed with an Outperform at Oppenheimer - TipRanks
Mind Medicine’s Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
Mind Medicine (MNMD) Gains Positive Outlook with Oppenheimer's O - GuruFocus
Mind Medicine (MindMed)’s (MNMD) “Buy” Rating Reiterated at Chardan Capital - Defense World
What are the latest earnings results for Mind Medicine (MindMed) Inc.Invest confidently with advanced analysis tools - Jammu Links News
Why is Mind Medicine (MindMed) Inc. stock attracting strong analyst attentionFree Trading Psychology Coaching - Jammu Links News
How does Mind Medicine (MindMed) Inc. compare to its industry peersGet timely alerts on market opportunities - Jammu Links News
What is the dividend policy of Mind Medicine (MindMed) Inc. stockOutstanding capital returns - Jammu Links News
What analysts say about Mind Medicine (MindMed) Inc. stockAccelerate your capital gains today - Jammu Links News
Is it the right time to buy Mind Medicine (MindMed) Inc. stockHigh-yield portfolio picks - Jammu Links News
How does Mind Medicine (MindMed) Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Mind Medicine (MindMed) Inc. stock expected to show significant growthAchieve breakthrough investment performance - Jammu Links News
How volatile is Mind Medicine (MindMed) Inc. stock compared to the marketAI Powered Signals For Consistent Profits - jammulinksnews.com
MindMed (MNMD) Q2 Net Loss Jumps 625% - The Globe and Mail
MindMed Reports Strong Q2 2025 Financial Results - The Globe and Mail
Unraveling the Sharp Drop in Mind Medicine (MNMD.O): A Technical and Order-Flow Deep Dive - AInvest
Mind Medicine Inc's Q2 2025 Earnings Call Highlights: Strong Financial Position and Strategic Advancements in MM-120 ODT Trials - AInvest
Earnings call transcript: MindMed Q2 2025 reveals cash runway into 2027 - Investing.com Canada
Mind Medicine (MindMed) Q2 2025 Earnings Call Transcript - MarketBeat
Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
Mind Medicine Advances Phase III Trials for Anxiety and Depression Treatment, Appoints New CFO - AInvest
Real time social sentiment graph for Mind Medicine (MindMed) Inc.Market Downturn Defense Strategy Analysis - Newser
MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway - Investing.com Nigeria
MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway By Investing.com - Investing.com South Africa
MindMed Reports Q2 2025 Financial Results and Business Updates - Business Wire
What is the risk reward ratio of investing in Mind Medicine (MindMed) Inc. stockEntry Signal Growth Plan That Work - Jammu Links News
What are the technical indicators suggesting about Mind Medicine (MindMed) Inc.Chart Pattern Forecasts For Consistent Profits - Jammu Links News
Mind Medicine Inc Azioni (MNMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):